Compumedics reports record revenue of $60.3M

• Compumedics achieved a record shipped and invoiced revenue of approximately $60.3 million for the 2026 financial year.
• The company's shares increased 14.58% to $0.28 following the business update.
• The revenue expansion was primarily driven by a 70% increase in software-as-a-service recurring revenues.

Medical device manufacturer Compumedics (ASX:CMP) delivered record annual revenue of approximately $60.3 million following a surge in platform sales.

This full-year revenue represents a growth rate of approximately 18% compared to the 2025 financial period.

Software-as-a-service recurring revenues from the Somfit and Nexus 360 platforms increased by approximately 70% year-on-year.

Total sales orders reached approximately $62.7 million, while non-executive director Christopher R. Barys resigned from the board.

Following the announcement, the Compumedics share price was up at $0.28.

Operationally, the firm resolved helium-related supply and pricing disruptions that had previously delayed brain imaging system shipments.

The company stated that it enters the new financial year targeting double-digit revenue gains and accelerated earnings growth.